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Abstract  
Drug release from mesoporous silica systems has been widely investigated in vitro using USP 
Type II (paddle) dissolution apparatus. However, it is not clear if the observed enhanced in 
vitro dissolution can forecast drug bioavailability in vivo. In this study, the ability of different 
in vitro dissolution models to predict in vivo oral bioavailability in a pig model was 
examined. The fenofibrate-loaded mesoporous silica formulation was compared directly to 
a commercial reference product, Lipantil Supra®. Three in vitro dissolution methods were 
considered; USP Type II (paddle) apparatus, USP Type IV (flow-through cell) apparatus and a 
USP IV Transfer model (incorporating a SGF to FaSSIF-V2 media transfer). In silico modelling, 
using a physiologically based pharmacokinetic modelling and simulation software package 
(Gastroplus™), to generate in vitro/in vivo relationships was also investigated. The study 
demonstrates that the in vitro dissolution performance of a mesoporous silica formulation 
varies depending on the dissolution apparatus utilised and experimental design. The 
findings show that the USP IV transfer model was the best predictor of in vivo bioavailability. 
The USP Type II (paddle) apparatus was not effective at forecasting in vivo behaviour. This 
observation is likely due to hydrodynamic differences between the two apparatus and the 
ability of the transfer model to better simulate gastrointestinal transit. The transfer model is 
advantageous in forecasting in vivo behaviour for formulations which promote drug 
supersaturation and as a result are prone to precipitation to a more energetically 
favourable, less soluble form. The USP IV transfer model could prove useful in future 
mesoporous silica formulation development. In silico modelling has the potential to assist in 
this process. However, further investigation is required to overcome the limitations of the 
model for solubility enhancing formulations. 
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1. Introduction 
Recent developments in drug discovery have increased the number of BCS Class II drug 
candidates. These drug molecules pose significant challenges in terms of oral drug delivery 
and biopharmaceutics [1, 2]. Drug loading onto a mesoporous silica substrate using various 
novel loading approaches (including solvent methods, supercritical fluid and microwave 
irradiation), has been considered as a possible formulation strategy to improve drug 
aqueous solubility [3-6]. Drug molecules are stabilized on the silica surface and within silica 
pores in an amorphous state, which enhances the drug’s dissolution rate [7, 8]. However, 
further research is required to fully understand the behaviour of these mesoporous silica 
formulations in vitro and in vivo.  
Van Speybroeck et al published two in vivo studies which investigated the impact of 
supersaturation and precipitation on release from these formulations [9, 10]. However, the 
total number of mesoporous silica in vivo studies published in the literature is limited [11-
13]. The majority of in vitro dissolution experiments conducted involving mesoporous silica 
formulations have utilised traditional methods: USP Type II apparatus and sink conditions 
with simple buffer solutions as the dissolution medium [14-18].  There are limitations 
associated with this traditional approach to dissolution which are of particular relevance to 
poorly water-soluble drug candidates [19]. Augustijns et al recommended that non-sink in 
vitro dissolution conditions are required for silica-based formulations to provide meaningful 
data that can be correlated with in vivo studies [20]. Furthermore, as the simple buffer 
solutions used in most in vitro experiments do not represent all aspects of the fluid 
composition of the gastrointestinal (GI) tract, it is preferable to use biorelevant media that 
better simulate physiological fluids [21]. The Type IV dissolution apparatus offers the ability 
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to change the dissolution medium during an experiment, which results in conditions that 
more closely reflect the pH gradient associated with transit through the GI tract [22]. It has 
been reported that the Type IV dissolution apparatus is a better simulator of in vivo 
hydrodynamics than the paddle apparatus [23]. However, the number of studies which 
utilise this model are limited and published data with regards to the superiority of the Type 
IV flow-through cell over the Type II apparatus is not in agreement [24, 25]. 
In this study, we compared the ability of in vitro dissolution methods to predict in vivo 
performance of an oral mesoporous silica drug delivery system. Type II and Type IV 
dissolution apparatus were employed to investigate the release of a poorly water-soluble 
drug, fenofibrate, from this formulation. This study is the first to our knowledge to use the 
Type IV apparatus to assess dissolution of a BCS Class II drug-loaded mesoporous silica 
system. Fenofibrate was chosen as the model compound in this study. Fenofibrate is a 
neutral, lipophilic drug (log p = 5.2), which is practically insoluble in water [26]. The in vivo 
performance of the mesoporous silica formulation was assessed following oral 
administration in a fasted pig model and compared to the commercial fenofibrate  
formulation, Lipantil Supra® (which utilises NanoCrystal® technology) [27].  
In vitro/in vivo correlations (IVIVC) and in vitro/in vivo relationships (IVIVR) are being 
increasing used as part of the formulation ‘toolbox’ to build on knowledge from in vitro data 
and forecast formulation effects. The best candidates for in vitro/in vivo correlations are 
drugs where dissolution is the rate-limiting step to drug absorption and biorelevant 
dissolution models are used in the experimental design [28]. In this study, data from the in 
vitro and in vivo experiments was analysed using a physiologically-based pharmacokinetic 
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modelling and simulation software package (Gastroplus™) to generate IVIVR. The potential 
benefits and limitations of this in silico modelling approach are discussed.  
 
2. Material and Methods 
2.1. Materials 
Fenofibrate was purchased from Kemprotec Ltd. (United Kingdom). SBA-15 was obtained 
from Glantreo Ltd. (Ireland). Liquid carbon dioxide was supplied by Irish Oxygen Ltd. 
(Ireland). Fenofibric acid, sodium taurocholate (>95%) and pepsin (from porcine gastric 
mucosa, 800-2500 units/mg protein) were obtained from Sigma Aldrich (Ireland). Lecithin 
(Lipoid E PC S, >98% pure) was kindly donated by Lipoid GmbH, Germany. All other 
chemicals and solvents were of analytical grade or HPLC grade, and purchased from Sigma-
Aldrich (Ireland). Lipantil® Supra 145mg film-coated tablets were sourced through a local 
community pharmacy.  
2.2. Preparation of Fenofibrate-Loaded Silica Formulation 
Fenofibrate loaded SBA-15 was prepared according to the method previously described by 
Ahern et al [14]. The drug and mesoporous silica (2 g) at a drug:silica mass ratio of 2:3 were 
combined in a BC 316 high-pressure reactor (High Pressure Equipment Company, USA) and 
stirred using a magnetic stirring. The reactor was heated to 40 °C using heating tape and 
maintained at this temperature for the duration of the experiment. Temperature was 
monitored using a temperature monitor (Horst GmbH, Germany). The reactor cell was filled 
with liquid CO2 and a high pressure pump (D Series Syringe Pump 260D, Teledyne ISCO, USA) 
was used to pump additional CO2 to a final processing pressure (27.58 MPa). After 12 h, the 
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cell was depressurised rapidly by venting the CO2. The processed material was collected 
from the cell and stored in a desiccator prior to analysis.  
2.3. Drug Content Quantification 
The fenofibrate content of the silica formulation was determined by thermogravimetric 
analysis (TGA), using a TGA 500 instrument (TA Instruments Ltd., United Kingdom). Samples 
in the weight range 2–10 mg were loaded onto tared platinum pans and heated from 
ambient temperature to 900 °C, at a heating rate of 10 °C/min under an inert 
N2 atmosphere.  Samples were analysed in triplicate. The drug quantity was calculated 
based on the weight loss between 100 and 900 °C, corrected for the weight loss over the 
same temperature range for a silica (SBA-15) reference sample [4]. TGA thermograms were 
analysed using Universal Analysis 2000 software (TA Instruments Ltd., United Kingdom). 
Drug-loading efficiency was calculated using Equation 1: 
                             
                        
                             
        (Equation 1) 
The theoretical drug-loading was based on mass fraction of drug and silica used to prepare 
samples. 
2.4. Solubility Measurements 
Solubility studies were carried out by the addition of excess fenofibrate to biorelevant 
media using a standardised shake-flask method with a shake time of 24 h at 37 °C [29]. 
Simulated gastric fluid (SGF) was prepared as outlined in the USP NF 26 [30]. FaSSIF-V2 was 
prepared as outlined in the literature [21]. Samples (2 ml volume) were removed at 24 h and 
centrifuged at 16,500 g for 13 min using a Hermle z233M-2 fixed angle rotor centrifuge, 
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(HERMLE Labortechnik GmbH, Germany). The supernatant was removed and centrifuged 
again under the same conditions. The resultant supernatant was analysed using HPLC 
following dilution with acetonitrile.  
2.5. In Vitro Dissolution Experiments 
USP Type II (Paddle) Apparatus: Dissolution studies were carried out in triplicate with an 
Erweka® DT600 dissolution test system (Erweka GmbH, Germany). Tests were performed in 
500 ml of SGF or FaSSIF-V2 at 37 ± 0.5 oC at a paddle rotation of 75 rpm. Drug-loaded silica 
samples equivalent to 50 mg fenofibrate were placed in the dissolution medium. The dose 
of 50 mg fenofibrate in the release media corresponded to a theoretical concentration of 
100 µg/ml following complete dissolution which represents a supersaturated state in SGF 
and FaSSIF-V2 (see fenofibrate solubility values in section 3.2). Samples of 4 ml volume were 
withdrawn at 1, 5, 10, 15, 30, 60 and 120 min intervals (with additional samples taken from 
the FaSSIF-V2 media at 180 and 240min). Samples were immediately replaced with an equal 
volume of fresh, pre-warmed medium. The withdrawn samples were filtered through a 0.20 
µm PES membrane filter (Filtropur S0.2, Sarstedt AG & Co., Germany). Samples were diluted 
with acetonitrile prior to analysis by HPLC.  
USP Type IV (Flow-Through Cell) Apparatus: Dissolution studies were carried out in triplicate 
with an Erweka® flow-through apparatus (DFZ 720 with HKP 720 piston pump) equipped 
with 22.6 mm diameter cells. The temperature of the water bath was maintained at 37 oC. 
The dissolution medium of either 100 ml SGF or FaSSIF-V2, recirculated in closed loop model 
at a flow rate of 4 ml/min. A glass ball (5mm) and 1 g of glass beads (1mm) were placed in 
the bottom of the cone to ensure laminar flow of the jet of fluid entering the cell. 
Formulation samples equivalent to 10 mg fenofibrate were placed on top of the glass beads. 
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Undissolved fenofibrate particles were retained in the sample holder using a glass fibre filter 
located in the top of the cone. The dose of fenofibrate in the release media thus 
corresponded to a theoretical concentration of 100 µg/ml which represents a 
supersaturated state in SGF and FaSSIF-V2 (see fenofibrate solubility values in section 3.2). 
Samples of 1 ml volume were withdrawn at 1, 5, 10, 15, 30, 60 and 120 min intervals (with 
additional samples taken from the FaSSIF-V2 media at 180 and 240 min). Samples were 
immediately replaced with an equal volume of fresh, pre-warmed medium. The withdrawn 
samples were filtered through a 0.20 µm PES membrane filter (Filtropur S0.2, Sarstedt AG & 
Co., Germany). Samples were diluted with acetonitrile and analysed by HPLC. In addition to 
conducting individual dissolution experiments using the Type IV apparatus employing either 
SGF or FaSSIF-V2, a dissolution experiment involving a SGF to FaSSIF-V2 transfer method 
was conducted. Samples were removed as described above for the initial SGF stage of the 
experiment up to the 120 min time point. The SGF dissolution medium supply beaker was 
then removed and replaced with a beaker containing 100 ml of FaSSIF-V2 medium. 
Subsequent sampling time points were taken at 1, 5, 10, 15, 30, 60 and 120, 180 and 240 
min) following transfer from SGF to FaSSIF-V2 medium.  
2.6. In vivo oral bioavailability study 
The study was carried out under licences issued by the department of Health, Ireland as 
directed by the Cruelty to Animals Act Ireland and EU Statutory Instructions. Local university 
ethical committee approval was also obtained. The data from this intravenous study has 
been previously used for the calculation of fenofibrate clearance in pigs to allow absolute 
bioavailability to be determined in separate studies [31, 32]. Female landrace pigs (17–19 
kg) housed at the University College Cork’s Biological Services Unit were used for these 
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experiments. Animals were fasted for 16 h before experimentation. On day 1, an indwelling 
intravenous catheter was inserted in the jugular vein, under general anaesthesia, as 
previously described [33]. Following recovery, pigs were returned to their pens and allowed 
access to food and water.   
On day 2 (following an overnight fast), the oral formulations containing a dose of 67 mg 
fenofibrate were administered in gelatin capsules with the aid of a dosing gun.  After dosing 
the pigs received 50 ml of water via an oral syringe. Blood samples (5 ml) were withdrawn 
from the jugular line at time zero (pre-dosing) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h 
intervals post dosing. Water was available ad libitum throughout the study period and the 
animals were fed 8 h post-dose. For the intravenous treatment (i.v.), animals were 
administered 25 mg fenofibrate by slow infusion, over 2 min, via 3 ml of a solution 
containing 8.33 mg/ml fenofibrate in 80 %w/w ethanol and 20 %w/v physiological saline 
into an ear vein. Blood sampling was performed as outlined above. All blood samples were 
collected in heparinised tubes (Sarstedt, Germany) and centrifuged immediately after 
withdrawal at 3220 g for 5 minutes at 4 °C. Plasma samples were stored at −80 °C prior to 
HPLC assay.  
2.7. Quantitative Analysis of Fenofibrate 
HPLC analysis of the in vitro dissolution samples was performed using an Agilent 1200 series 
HPLC system with an UV/Vis detector (Agilent Technologies, USA). A reversed-phase column 
(Kinetex C-18, 150 × 4 mm x 2.6 µm, Phenomenex Ltd. UK), mobile phase of acetronitrile 
and water (80:20) at a flow rate of 1 ml/min and injection volume of 20 µl were employed. 
The wavelength for fenofibrate detection was set at 286 nm and retention time was 4.5 
min. 
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In vivo plasma samples were quantified for fenofibric acid (the major active metabolite of 
fenofibrate). Based on a method by Griffin et al [32], a volume of 0.5 ml plasma was spiked 
with 50 µl of internal standard (sulindac) and vortexed. Proteins were precipitated through 
the addition of 0.5 ml of 25 %w/v NaCl solution and 1 ml of 1 %w/v H3PO4 in methanol with 
thorough mixing. Samples were centrifuged at 11,500 g for 9 min using a Hermle z233M-2 
fixed angle rotor centrifuge (HERMLE Labortechnik GmbH, Germany). The supernatant (20 
µl) was injected onto a Synergi C18 reversed phase column (250 x 4.6 x 2.6 µm, 
Phenomenex Ltd. UK) using the Agilent system described above. The mobile phase consisted 
of acetronitrile and water (80:20) adjusted to pH 2.5. The flow rate was set at 1 ml/min 
resulting in elution of fenofibric acid and fenofibrate at 6.5 and 10.5 min, respectively. The 
concentration of drug was determined at 286 nm.  
2.8. In vitro and in vivo data analysis 
 The extent of fenofibrate release was calculated as area under the dissolution curve (AUC) 
using Prism (ver. 5, GraphPad Software Inc., USA.). Peak fenofibrate concentrations (Cmax) 
and the time for their occurrence (Tmax) were noted directly from the individual dissolution 
profiles. Intravenous pharmacokinetic parameters were fitted to a two compartment model 
using the PKPlus™ module in Gastroplus™ (ver. 8.6, Simulations Plus Inc., USA). AUC for 
fenofibric acid after oral administration of both formulations was calculated for 24 h post-
dosing using Prism. The peak plasma concentrations (Cmax) and the time for their occurrence 
(Tmax) were noted directly from the individual plasma concentration vs. time profiles. 
Absolute bioavailability (Fabs) was calculated according to Equation 2:  
       
        
        
     
         
         
   (Equation 2) 
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Relative bioavailability was calculated as the ratio of AUC0→24 obtained after oral 
administration of the silica and Lipantil Supra® formulations. The relative extent of 
fenofibrate release from both formulations in the three different dissolution models was 
calculated as the ratio of AUC values.  Results are reported as mean ± standard deviation.  
In vitro dissolution data comparing the two formulations was tested for significance 
(p < 0.05) using a two-tailed, independent sample t-test, assuming Gaussian distribution and 
equal variance. Statistical analysis of the Cmax and AUC values from the dissolution profile for 
both formulations were performed using a one-way analysis of variance (ANOVA) and post 
hoc Tukey’s multiple comparisons test. P-values of <0.05 were considered significant. 
Paired t-tests were used to determine the statistical significance (p < 0.05) of calculated in 
vivo bioavailability and pharmacokinetic results, as each animal acted as its own control in 
this crossover study. All statistical analyses were performed using GraphPad Prism Version5, 
USA. 
2.9. In Silico Predictive Modelling 
In silico modelling was conducted using GastroPlus™ (ver. 9.0, Simulations Plus, USA.). The 
ADMET Predictor™ module was used to estimate fenofibrate physiochemical characteristics. 
Predictive mathematical models were generated using the IVIVCPlus™ component of the 
software. In this study, the Loo-Riegelman two-compartment method was implemented to 
deconvolute the in vivo oral plasma concentration profiles using intravenous data as 
previously published [31, 32]. An IVIVR was generated by correlating the fraction of drug 
absorbed in vivo with the fraction of drug dissolved in vitro (for the initial period of 
fenofibrate dissolution i.e. time points up to Tmax). The data was then convoluted to 
generate a predicted plasma concentration-time profile, which was compared with the 
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observed in vivo data. The software displayed Cmax and AUC for the observed and predicted 
profiles. It also generated the prediction error between the two profiles which can be used 
to evaluate the predictability of the correlation as described by the FDA [34]. The FDA 
require an average absolute percentage error (%PE) of 10 % or less for AUC and Cmax for 
internal predictability. The %PE for each formulation should not exceed 15 %. 
3. Results 
3.1. Drug Content Quantification 
Fenofibrate loading onto SBA-15 was 251.3mg drug/g silica (25.13 % ± 0.68). The low 
variability observed in the drug loading for this SC-CO2 process is indicative of a 
homogeneous drug distribution on the silica surface [5]. The drug loading efficiency, 
calculated using Eq. 1, was 62.83%. The loading technique converted the fenofibrate to a 
non-crystalline solid phase as previously reported by Ahern et al [14].  
3.2. Fenofibrate Solubility  
Fenofibrate solubility in SGF was determined as 0.17 ± 0.05 µg/ml.  Fenofibrate solubility in 
FaSSIF-V2 (3.64 ± 0.62 µg/ml) was significantly enhanced, which indicates that fenofibrate is 
solubilised in the micelles of simulated intestinal fluid [29].  
3.3. In Vitro Dissolution  
3.3.1. USP Type II (Paddle) Apparatus 
Dissolution experiments using the USP Type II (paddle) method were conducted under 
supersaturated conditions (580 times drug saturated solubility in SGF and 27 times the 
saturated solubility in FaSSIF-V2). There was no detectable release of fenofibrate from the 
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silica formulation in SGF. This could be explained by the mechanism of drug release 
previously published for mesoporous silica systems in vitro [35, 36]. These reported 
dissolution profiles involve an initial burst release (where the majority of loaded drug is 
released) followed by a sustained secondary release [37]. As a result of the drug’s low 
solubility in conditions of low pH and the absence of additional excipients to enhance 
solubility or stabilise dissolution, the release of fenofibrate was not quantifiable (the limit of 
quantification was 200 ng/ml). Fenofibrate dissolution from the Lipantil Supra® formulation 
resulted in a sustained supersaturation (Fig. 1). Drug release increased over the first 15 mins 
(Cmax 2.79 ± 0.70 µg/ml), before reaching a plateau for the remainder of the experiment. The 
supersaturation ratio during this plateau phase (defined as C/Cs, where Cs is the saturated 
solubility) was 15.49. This marked solubility increase is most likely due to the composition of 
the Lipantil Supra® formulation which contains surfactants, sodium lauryl sulfate (SLS) and 
sodium docusate. SLS has been previously shown to significantly increase the solubility and 
dissolution rate of fenofibrate through a combination of wetting, micellar solubilisation and 
deflocculation [38, 39].  
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Fig 1. Fenofibrate release profiles for Lipantil Supra® in SGF at 37oC; () indicates Type IV 
apparatus, () indicates Type II (paddle) apparatus. Dotted line indicates equilibrium 
solubility of fenofibrate in SGF. (n=3, Y error bars indicate standard deviation) 
 
Compared to SGF, fenofibrate release from both formulations was significantly higher in 
FaSSIF-V2 due to the greater amount of physiologically relevant surfactants in the medium. 
FaSSIF-V2 allows for increased micellar solubilisation of the drug (Fig. 2). However, the 
extent of release from the commercial product was significantly higher than release from 
the silica formulation (p<0.001). Fenofibrate release from the silica formulation in FaSSIF-V2 
media exhibited the classic ‘burst release’ profile characteristic of silica formulations [35, 
36]. Drug dissolution maintained supersaturation levels for the first 30 min of the 
experiment (Cmax = 5.76 ± 0.28 µg/ml, supersaturation ratio of 1.58). However, at 60 min, 
release had dropped below fenofibrate thermodynamic solubility levels. Fenofibrate release 
from the Lipantil Supra® formulation demonstrates high levels of supersaturation (Cmax = 
53.68 ± 2.73 µg/ml, peaking at a supersaturation ratio of 14.74). Drug dissolution decreases 
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after 30 min for the remainder of the experiment but never drops below supersaturation 
levels over the 4 h experiment.  
 
Fig. 2 Fenofibrate release profiles from mesoporous silica formulation () and Lipantil 
Supra® (◆) in FaSSIF-V2 media at 37oC for Type II (paddle) apparatus. Dotted line indicates 
fenofibrate solubility in FaSSIF-V2 media. (n=3, Y error bars indicate standard deviation) 
 
A summary of the in vitro release parameters are detailed in Table 1. The high levels of 
release observed in this dissolution experiment with FaSSIF-V2 alone might not be indicative 
of in vivo performance. In vivo, the formulation will experience the low pH of the stomach 
initially (where the drug has extremely low solubility), which may cause significant 
precipitation. Precipitation to a lower energetically favourable, less water-soluble form can 
have a dramatic effect on drug release following transit to the small intestine environment 
mimicked by FaSSIF-V2. In vitro experiments simulating this transition were hence 
conducted and are described in the section 3.3.3.   
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Table 1. Summary of in vitro dissolution parameters. Mean values +/- standard deviation are 
provided (n=3)  
Type II (Paddle) Apparatus 
Formulation C
max FASSIF
 (µg/ml) AUC
240min
 
FASSIF 
(µg/ml.min) T
max 
(min) 
Mesoporous Silica 5.76±0.28 631±9 10±0 
Lipantil Supra® 53.68±2.73 7493±1177 20±8.7 
Type IV (Flow Through Cell) Apparatus 
Formulation C
max FASSIF
 (µg/ml) AUC
240min
 
FASSIF 
(µg/ml.min) T
max 
(min) 
Mesoporous Silica 2.96±0.79 398±81 20±8.7 
Lipantil Supra® 4.45±0.29 924±36 15±0 
Transfer Model 
Formulation C
max FASSIF
 (µg/ml) AUC
240min
 
FASSIF 
(µg/ml.min) T
max 
(min) 
Mesoporous Silica 1.49±0.07 322±18 160±69.3 
Lipantil Supra® 2.04±0.06 364±30 240±0 
 
3.3.2. USP Type IV (Flow-Through Cell) Apparatus 
Non-sink conditions in the Type IV model were equivalent to those employed for USP II 
apparatus (580 times drug equilibrium solubility in SGF and 27 times the saturated solubility 
in FaSSIF-V2). Similar to results observed for the Type II model, fenofibrate release from the 
mesoporous silica formulation in SGF was not quantifiable. Fenofibrate release from Lipantil 
Supra® in SGF reached supersaturation levels for the first 30 min of the experiment (Cmax = 
0.41 ± 0.09µg/ml) but at 60 min release had fallen to the drug’s equilibrium solubility (Fig. 
1). As illustrated in Fig. 1, the Cmax level and the extent of fenofibrate release was 
significantly higher using the Type II apparatus compared to the Type IV flow through cell (p 
< 0.005). This indicates that hydrodynamic differences between the two model apparatus 
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have a significant impact on the dissolution process and the final dissolution profile.  This is 
discussed in more detail in Section 4.  
Similar to the Type II apparatus, both formulations exhibit enhanced drug release in the 
FaSSIF-V2 media using the Type IV apparatus. The extent of release from Lipantil Supra® was 
significantly higher than that of the silica formulation (p < 0.001, Fig. 3). However, release 
from the SBA-15 system does not reach supersaturation levels in the Type II apparatus. 
Fenofibrate release from the Lipantil Supra® formulation peaks at 15 min (Cmax = 4.45 ± 
0.29µg/ml, supersaturation ratio of 1.22), then drops to remain at the thermodynamic 
solubility level for the duration of the four hour experiment. A summary of in vitro release 
parameters is provided in Table 1. 
 
 
Fig. 3 Fenofibrate release profiles from mesoporous silica formulation () and Lipantil 
Supra® (◆) in FaSSIF-V2 media at 37oC for Type IV (flow through cell) apparatus. Dotted line 
indicates fenofibrate solubility in FaSSIF-V2 media. (n=3, Y error bars indicate standard 
deviation) 
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3.3.3. Transfer Model in USP Type IV (Flow-Through Cell) Apparatus 
In the Type IV transfer model, samples were first exposed to SGF for 120 min followed by 
FaSSIF-V2 media for 240 min, to simulate GI transit in the dissolution model. As described in 
section 3.3.2, the Lipantil Supra® formulation reached supersaturation levels in the SGF,  
whereas release from the mesoporous silica system was unquantifiable (Fig. 4). The shape 
of the dissolution profile for the silica formulation in the transfer model (FaSSIF-V2 stage) is 
different from that of the Type II or Type IV FaSSIF-V2 profiles (Fig. 4). The classic ‘burst’ 
release in FaSSIF-V2 media was not evident using the transfer model and neither 
formulation reached supersaturation levels in the FaSSIF-V2 media (Cmax = 2.04 ± 0.06 µg/ml 
for Lipantil Supra® and Cmax= 1.49 ± 0.07 µg/ml for the silica formulation). It is probable that 
the reduction in the extent of dissolution in FaSSIF-V2 is due to fenofibrate precipitation 
upon exposure to SGF media for both formulations. While Cmax for Lipantil Supra® was 
significantly higher than for the silica system (p < 0.001), there was no significant difference 
in the overall extent of fenofibrate release over the duration of the experiment (p > 0.1). 
This is in contrast to the differences in the extent of fenofibrate release for both 
formulations in FaSSIF-V2 media alone in USP Type II and USP Type IV apparatus (Table 1). 
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Fig. 4 Fenofibrate release profiles from mesoporous silica formulation () and Lipantil 
Supra® (◆) in USP IV Transfer Model at 37oC (incorporating SGF to FaSSIF-V2 transfer). 
Dotted line indicates fenofibrate solubility in SGF and FaSSIF-V2 media. (n=3, Y error bars 
indicate standard deviation) 
3.4. In Vivo Oral Bioavailability  
The plasma concentration profiles obtained following oral administration of 67 mg of 
fenofibrate, in the form of either Lipantil Supra® or the silica formulation, to fasted pigs are 
displayed in Fig. 5. A maximum plasma concentration of 3.96 ± 1.29 µg/ml was observed for 
Lipantil Supra® at 5.0 ± 2.4 h. The absorption of fenofibrate from the silica formulation was 
slower with a Cmax of 2.34 ± 1.23 µg/ml at Tmax  9.5 ± 3.0 h. A summary of the in vivo 
parameters for both formulations is provided in Table 2. The classical ‘burst’ release of the 
silica formulation, observed during both dissolution experiments conducted in FaSSIF-V2 
alone was not evident in the in vivo pig model. No corresponding sharp onset of fenofibrate 
absorption was observed for the silica formulation. A slower rate of drug absorption was 
noted which indicates a slower release profile as noted in the transfer model FaSSIF-V2 
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phase. This indicates that the transfer model better simulates how the formulation will 
perform in vivo.  
 
 
Fig. 5 Plasma concentration of fenofibric acid vs. time profiles after oral administration of 67 
mg fenofibrate to fasted pigs, () indicates mesoporous silica formulation, (◆) indicates 
Lipantil Supra®, () indicates intravenous preparation. (n=4, Y error bars indicate standard 
deviation 
Table 2. Summary of in vivo pig model parameters. Mean values +/- standard deviation are 
provided (n=4). (*) denotes values which are significantly different (p<0.05). 
Formulation Cmax (µg/ml) AUC0→24h Tmax Fabs0→24h 
Mesoporous Silica 2.34±1.23* 26502±11377 9.5±3 54.55±23.42 
Lipantil Supra® 3.96±1.29* 34536±12527 5±2.4 71.08±25.78 
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Absolute bioavailability was determined for both formulations relative to an intravenous 
control. An absolute bioavailability of 54.55 ± 23.42% was observed for the silica 
formulation which was not significantly different to that of the commercial product, 71.08 ± 
25.78% (p > 0.1). This confirms the potential of the silica system to enhance the 
bioavailability of fenofibrate. However the silica formulation has a slower onset of release 
when compared with the Lipantil Supra® (Tmax of 5.0 ± 2.4h and 9.5 ± 3.0h, respectively). The 
relative bioavailability in vivo of the silica formulation versus Lipantil Supra® was 73.33 ± 
17.07%.  
To enable comparison of the in vitro dissolution and the in vivo bioavailability results, the 
ratio of extent of drug release (as a ratio of the silica formulation to Lipantil Supra® AUC) for  
the Type II, Type IV and USP IV transfer methods were plotted adjacent to the relative 
bioavailability of both formulations in vivo (Fig. 6). Fig. 6 highlights the differences between 
the extent of release from both formulations using the Type II (A) and Type IV (B) apparatus 
and similarity using the Type IV Transfer Model (C) and oral bioavailability in the in-vivo pig 
model (D). To facilitate further quantitative comparison, the ratio of extent of release of the 
silica vs. commercial formulation were calculated (Fig. 7). The ratios of extent of release 
determined for the Type II and Type IV dissolution data were 8.55±1.28% and 43.32±10.50% 
respectively. In contrast, the ratio of extent of fenofibrate release from the Type IV transfer 
method data was 89.16±12.49%. This ratio did not significantly differ from the relative in 
vivo oral bioavailability of these formulations (p > 0.05, Fig.7).  This indicates that the USP IV 
transfer method was a superior predictor of in vivo performance compared to USP II and IV 
with FaSSIF-V2 alone.  
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A       B 
 
 
 
 
 
 
 
C       D 
 
Fig. 6 Extent of release (AUC) and oral bioavailability of fenofibrate from a mesoporous silica 
and Lipantil Supra® formulations. A = extent of release using Type II apparatus, B = extent of 
release using FaSSIF-V2 media in a Type IV apparatus, C = extent of release using Type IV 
Transfer model, D = oral bioavailability determined using an in vivo pig model. Graphs show 
AUC over 240 min for Type II and Type IV, 360 min for Transfer and 24 hours for in vivo pig 
model). (n=3 for in vitro dissolution models, n=4 for in vivo pig bioavailability model, Y error 
bars indicate standard deviation) 
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Fig 7. Ratio of extent of release of fenofibrate from the silica formulation vs. the commercial 
product, Lipantil Supra®, for the in vitro dissolution experiments and the in vivo pig study. 
Graphs show ratio of AUC release of silica formulation: Lipantil Supra® over 240 min for 
Type II and Type IV, 360 min for Transfer and 24 hours for in vivo pig model). (n=3 for in vitro 
dissolution models, n=4 for in vivo pig bioavailability model, Y error bars indicate standard 
deviation) 
3.5. In Silico of IVIVR Modelling  
The IVIVRs for the two formulations were generated using Gastroplus™ software. Previously 
published intravenous data was used to deconvolute the in vivo oral plasma concentration 
profiles using the Loo-Riegelman model [31, 32]. This two compartment model was chosen 
over a single compartment model as it has been reported that it is not possible to perform a 
rigorous pharmacokinetic analysis of an absorption process from oral data, unless the 
parameters of the model have first been derived from a separate intravenous experiment 
[40-42]. 
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No quantitative IVIVR could be established with the dissolution profiles from the Type II 
apparatus. IVIVRs could be generated for the Type IV (FaSSIF-V2) and the Type IV transfer 
Model (Fig. 8 and Fig. 9 respectively). Deconvolution of the Type IV data produced a linear 
best-fit correlation between the fraction of in vitro release and the fraction of absolute 
bioavailability (R2 = 0.883 for the silica formulation and R2 = 0.802 for the Lipantil Supra®).   
 
Fig. 8 Plasma concentration profiles for observed data (designated by the markers – () 
indicates mesoporous silica formulation, (◆) indicates Lipantil Supra®) and predicted 
plasma concentration-time profiles based on Type IV apparatus (designated by the solid 
lines - SBA-15 formulation (grey) and Lipantil Supra® (black))  
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Fig. 9 Plasma concentration profiles for observed data (designated by the markers – () 
indicates mesoporous silica formulation, (◆) indicates Lipantil Supra®) and predicted 
plasma concentration-time profiles based on USP IV Transfer model (designated by the solid 
lines - SBA-15 formulation (grey) and Lipantil Supra® (black))  
The mean absolute prediction error (MAE) was 5.18% for Cmax and 12.14% for AUC (this falls 
outside the FDA limit of 10% error). The full list of validation statistics is shown in Table 3. 
Optimisation of the deconvoluted transfer model data produced a second-order polynomial 
best-fit correlation (R2=0.771 for the SBA-15 formulation and R2=0.569 for the Lipantil 
Supra®). The MAE was 16.02% for Cmax and 15.55% for AUC, indicating the correlation is not 
as powerful as the Type IV model using FaSSIF-V2 media alone. The IVIVRs generated using 
Gastroplus™ software identify the Type IV apparatus as more effective at forecasting in vivo 
performance than the traditional paddle apparatus. However, it also suggests that the Type 
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IV dissolution, using FaSSIF-V2 alone, is the best prediction model. This is in contrast to data 
generated based on the extent of release discussed in section 3.4, which identified the Type 
IV Transfer model as the superior in vitro dissolution model. 
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Table 3. Summary of in vitro/in vivo relationship parameters.  Observed and predicted Cmax and AUC values and the correlation (R
2) between 
the observed and predicted plasma profiles generated by the Gastroplus™ IVIVCPlus® software are shown 
 
 
 
 
 
 
 
 
 
 
Cmax (µg/ml) AUC (µg/ml.h) Reconstructed Plasma 
Concentration-Time Profile 
from Convolution Tab (R
2
) Observed Predicted 
% Prediction 
Error 
Observed Predicted 
% Prediction 
Error 
Type IV Apparatus 
Mesoporous Silica  
Formulation 
1.854 1.993 -7.497 24.31 26.45 -8.803 0.883 
Lipantil Supra® 2.973 2.888 2.859 31.87 26.94 15.47 0.802 
USP IV Transfer Model 
Mesoporous Silica  
Formulation 
1.854 1.858 -0.216 24.31 28.97 -19.17 0.771 
Lipantil Supra® 2.973 2.027 31.82 31.87 28.07 11.92 0.569 
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4. Discussion 
To date mesoporous silica drug formulations have been widely investigated in vitro using 
USP Type II dissolution methods. There have been limited studies to determine whether the 
enhanced dissolution observed during these in vitro dissolutions tests are capable of 
forecasting their oral in vivo bioavailability. This study demonstrates that the in vitro 
dissolution performance of a mesoporous silica fenofibrate formulation varies depending on 
dissolution apparatus and experiment design. The findings show that a USP IV dissolution 
method incorporating a SGF to FaSSIF-V2 media transfer was the best predictor of in vivo 
oral bioavailability in a pig model.  
The study showed that the Cmax and AUC0→240min of both the commercial, Lipantil Supra®, 
and silica formulations in FaSSIF-V2 was significantly higher in the Type II compared to the 
Type IV apparatus. This observation is most likely due to hydrodynamic differences between 
the two dissolution models. The hydrodynamic properties of the Type II apparatus have 
been studied in detail and significant limitations have been recognised [19, 43-45]. The USP 
IV has the potential to operate at lower agitation rates than the paddle apparatus, resulting 
in lower fluid velocities considered to be more biorelevant [23, 46]. In vivo studies have 
shown that oral dosage forms can be exposed to small volumes of fluid in the gastro-
intestinal tract, which can also be modelled using the Type IV apparatus [47]. This is the first 
study, to our knowledge, which has used the Type IV flow-through apparatus to investigate 
release from drug-loaded mesoporous silica systems. It is also the first to compare the Type 
IV and the Type II apparatus directly to study the dissolution behaviour of this formulation 
approach. The similarity between the relative bioavailability of the silica formulation versus 
Lipantil Supra®, and the relative AUC (extent of release) of the formulations determined 
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using the USP IV transfer method, suggests that the USP IV is a more biorelevant in vitro test 
for these formulations. These results indicate that a supersaturation/precipitation process 
plays a significant role in the dissolution process of these systems and is best simulated 
using a transfer model.  
The advantages of using a transfer model to investigate formulation approaches which 
promote drug supersaturation, and are therefore prone to precipitation, have been 
reported by other groups [48-50].  Both formulations in this study utilise a supersaturation 
formulation strategy to enhance the oral bioavailability of fenofibrate [51]. The transfer 
model is a two compartment dissolution method to simulate GI transit from the stomach to 
the intestine. Fenofibrate release from the mesoporous formulation in SGF was below the 
HPLC assay detection limit. In contrast, fenofibrate release to supersaturation levels from 
Lipantil Supra® was evident in the gastric component of the transfer model. The exposure of 
the formulations to the acidic component in the transfer model affected their subsequent 
release profile in FaSSIF-V2 media. This is evident in the significant decrease in Cmax for both 
formulations in the Type IV transfer model compared to the Type IV FaSSIF-V2 only model. 
The exposure of high energy amorphous drug forms to an aqueous environment where it 
has very limited solubility is reported to promote recrystallization of the drug to a lower 
energy less soluble form [50]. Partial recrystallization and precipitation of drug in the silica 
formulation would explain the reduction in Cmax and AUC0→240min upon exposure to FaSSIF-V2 
media. 
The importance of controlling supersaturation in mesoporous silica formulations has been 
investigated by Van Speybroeck et al [9, 10]. Although supersaturation has been explored 
intensively in vitro, there is little evidence to support what occurs in the in vivo 
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environment. A recent study investigated the impact of gastrointestinal dissolution, 
supersaturation and precipitation of posoconazole in humans [52]. After administration of 
the formulations, gastric and duodenal fluids were aspirated and blood samples were 
collected in parallel. Supersaturation followed by significant intestinal precipitation was 
reported. This is in contrast to a study which reported limited duodenal precipitation for 
ketoconazole and dipyridamole in a human study [53]. In this study, previously reported in 
vitro dissolution dipyridamole data over-estimated the subsequent in vivo observations [48]. 
This indicates that drug supersaturation/precipitation is a complex process which can 
depend on the physiochemical properties of the drug, the formulation and physiological 
variables [50].  
The relationship between dosage form and physiological variables, such as the fed and 
fasted state warrant discussion. In the study, in-vitro dissolution studies were performed in 
FASSIF-V2 media designed to mimic the fastest state and pigs were dosed following an 
overnight fast, with food administered 8 hours post dose. The oral bioavailability of poorly 
water-soluble drugs, such as fenofibrate, is limited by their poor solubility within 
gastrointestinal fluid [54] and oral bioavailability can be variable depending on the food 
effect [55]. Formulation strategies have be shown to enhance bioavailability by reducing or 
eliminating the food effect [29, 31, 56]. For example, the commercial micronized fenofibrate 
formulation, Lipantil Micro®, displays food dependent bioavailability while the Lipantil® 
Supra formulation, encompassing NanoCrystal® technology, enables food independent 
administration and dose reduction [57]. These findings emphasise the need for studies of 
this nature which use in vivo reference data to optimize in vitro dissolution models and 
inform the development of bio-enabling formulation strategies.  
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The IVIVRs generated using the Gastroplus™ software support the relationships observed 
between the relative bioavailability of the formulations and their relative AUC (extent of 
release) determined from raw dissolution profiles. IVIVRs were determined for the Type IV 
FaSSIF-V2 model and the Type IV transfer model. No quantitative IVIVR could be determined 
for the Type II (paddle) apparatus. Correlations suggest that the Type IV apparatus with 
FaSSIF-V2 alone was better at forecasting in vivo performance than the transfer model. This 
finding can be explained by outlining the mechanism in which the model is generated and 
hence model assumption. The initial part of the dissolution profile (time points up to Cmax) 
was used to generate the IVIVR. The assumption of the model was that the second part of 
the dissolution profile, which corresponded to a reduction in drug concentration due to 
drug precipitation, may be an artefact of the in vitro dissolution model, particularly in the 
absence of an absorption sink. The initial dissolution phase was correlated with the 
deconvoluted in-vivo plasma profile and then re-convoluted to generate a predicted plasma 
profile.  
The IVIVR generated for the Type IV transfer model revealed significant limitations of the 
model; the MAE was 16.02% for Cmax and 15.55% for AUC and a large prediction error for 
the Lipantil Supra® Cmax of 31.82% was noted (more than double the FDA approved error 
limit of 15% for an individual formulation). This error can be attributed to the raw 
dissolution data for the Lipantil Supra®, specifically the concentration of fenofibrate at the 
fourth and fifth time point. This reduction (dip) in the release profile, while not statistically 
significant (p > 0.5) did significantly affected the in vitro/in vivo correlation simulated by the 
Gastroplus™ software. This sensitivity is a limitation of the current multi-step approach of 
deconvolution and correlation when comparing a small number of immediate release 
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formulations. Removal of fifth time point from the analysis improved the correlation but 
consequently reduced the power of the Type IV FaSSIF-V2 transfer model model IVIVR.  
In silico modelling requires further investigation to overcome the limitations outlined above. 
To date, modified release formulations have proved the most successful as regards 
development of effective IVIVR [58]. Work to improve in silico modelling for formulations 
which employ supersaturation to improve the bioavailability of poorly water-soluble drugs 
will be of significant benefit in their development.  
5. Conclusion 
This study demonstrates that the dissolution performance of a fenofibrate mesoporous 
silica formulation varies depending on the dissolution apparatus and the dissolution 
experimental design. The findings show that a USP IV transfer dissolution model was best at 
forecasting in vivo performance. This observation is most likely due to hydrodynamic 
differences between the two apparatus and the ability of the transfer model to better 
simulate GI transit. This is advantageous in forecasting in vivo behaviour for formulations 
which promote drug supersaturation and as a result are prone to precipitation. As this drug 
supersaturation/precipitation process is complex and depends on both formulation and 
physiological variables, studies which relate in vitro to in vivo data can help optimise in vitro 
models used in formulation development. Future work should focus on investigating the 
effect of silica formulation additives and dissolution media composition on in-vitro 
dissolution and the oral bioavailability of these systems. In silico modelling has the potential 
to assist in this process. However, further development is required to overcome the 
limitations outlined in this study for solubility enhancing formulations.  
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